Ralph Keller

Surgical cure for early rectal carcinomas (T1)

G Winde, H. Nottberg, Ralph Keller et al. · Diseases of the Colon & Rectum · 1996 · 410 citations

Medicine, Oncology, Surgery +17

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

Volker Kunzmann, Jens T. Siveke, Hana Algül et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 197 citations

Medicine, Oncology, Pharmacology +10

Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase <scp>II</scp> trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group

Ralf‐Dieter Hofheinz, S. Hegewisch-Becker, Volker Kunzmann et al. · International Journal of Cancer · 2021 · 103 citations · Full text

Medicine, Oncology, Pharmacology +14

Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP).

Volker Kunzmann, Uwe M. Martens, Hana Alguel et al. · Journal of Clinical Oncology · 2018 · 11 citations

Medicine, Oncology, Pharmacology +14

Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER).

Markus Moehler, Peter Thuss‐Patience, Baruch Brenner et al. · Journal of Clinical Oncology · 2017 · 11 citations

Medicine, Oncology, Pharmacology +9